[144] Jazz Pharmaceuticals plc SEC Filing

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc insider filing reports a proposed sale of 3,500 common shares to be executed on or about 10/03/2025 through Merrill Lynch on Nasdaq, with an aggregate market value of $490,000. The filing shows those shares were originally acquired as executive compensation on 10/04/2021 and 11/01/2021 (totaling 3,500 shares). The filer, identified as Bruce C Cozadd in prior sales records, disclosed three prior sales in the past three months totaling 9,000 shares for combined gross proceeds of $1,148,460 (sales on 08/01/2025, 09/02/2025, and 10/01/2025). The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

Positive

• None.

Negative

• Proposed sale of 3,500 shares on 10/03/2025 with aggregate value $490,000
• Prior insider sales of 9,000 shares in past three months for combined gross proceeds $1,148,460

Insights

Insider Transactions Analyst

TL;DR: Insider filed to sell 3,500 shares (~$490K) after selling 9,000 shares in the prior three months.

The filing documents a proposed sale of 3,500 Jazz Pharmaceuticals shares on 10/03/2025 via Merrill Lynch with an aggregate market value of $490,000. The shares were granted as executive compensation in 2021.

Records in the notice show prior insider sales by the same named seller totaling 9,000 shares for $1,148,460 across 08/01/2025, 09/02/2025, and 10/01/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3075B Hansen Way 1st Floor Palo Alto CA 94304	3500	490000	60658809	10/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/04/2021	Executive Compensation	Jazz Pharmaceuticals Plc			839	10/04/2021	n/a
Common	11/01/2021	Executive Compensation	Jazz Pharmaceuticals Plc			2661	11/01/2021	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bruce C Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin 4 L2 D04-E5W7	Common	10/01/2025	2000	263560
Bruce C Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin 4 L2 D04-E5W7	Common	09/02/2025	6000	771690
Bruce C Cozadd 5th Floor Waterloo Exchange Waterloo Road Dublin 4 L2 D04-E5W7	Common	08/01/2025	1000	113210

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did the Jazz Pharmaceuticals (JAZZ) Form 144 disclose?

The Form 144 discloses a proposed sale of 3,500 common shares (aggregate market value $490,000) to be sold on or about 10/03/2025 via Merrill Lynch on Nasdaq.

Who acquired the shares being sold and when were they acquired?

The shares were acquired as executive compensation from Jazz Pharmaceuticals plc on 10/04/2021 (839 shares) and 11/01/2021 (2,661 shares).

Has the filer sold Jazz shares recently?

Yes. The filing lists three sales in the past three months totaling 9,000 shares for gross proceeds of $1,148,460 on 08/01/2025, 09/02/2025, and 10/01/2025.

Through which broker will the proposed sale be executed?

The proposed sale is to be executed through Merrill Lynch, located at the address shown in the filing, on the Nasdaq exchange.

Does the filing state any undisclosed material information about Jazz Pharmaceuticals?

The signer represents that they do not know of any material adverse information about the issuer that has not been publicly disclosed, per the Form 144 statement.